CompletedNCT04101227
AD04 for Adults With Alcohol Use and Serotonin Gene Variants
About this title
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
Read the official source — NCT04101227Medication studyAges 18+Multiple countriesAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Burgas and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 1, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 302
- Sponsor
- Adial Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Behavioral
- Intervention type
- Psychotherapy / behavioral intervention, DEVICE, Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Croatia, Estonia, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT04101227
- Official title
Show the full official title
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults With Alcohol Use Disorder (AUD) and Selected Polymorphisms in the Serotonin Transporter and Receptor Genes
Get this study by email
Recruitment & locations
CompletedBurgas, Bulgaria · Kardzhali, Bulgaria · Pleven, Bulgaria
20 more locations
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Split, Croatia
- Zagreb, Croatia
- Tallinn, Estonia
- Helsinki, Finland
- Kuopio, Finland
- Oulu, Finland
- Pori, Finland
- Tampere, Finland
- Turku, Finland
- Liepāja, Latvia
- Riga, Latvia
- Strenči, Latvia
- Lublin, Poland
- Tuszyn, Poland
- Warsaw, Poland
- Borås, Sweden
- Uppsala, Sweden
Questions about this study
Who is behind this study?
The study sponsor is Adial Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including AD04 (ondansetron) and Matching placebo.
Who was this study for?
Listed age limits: from 18 years.
